Rang & Dale's Pharmacology¶
Ritter, J. M., Flower, R. J., Henderson, G., Loke, Y. K., MacEwan, D., & Rang, H. P. (2019). Rang & Dale's Pharmacology. Elsevier.
Cited by¶
2 citations across 2 artifacts.
Each citation links to the sentence it supports in the citing article.
Primes¶
- Antagonist
- The recognition interface is the site's shape complementarity; the activation function is the conformational change that, in the native agonist, opens downstream signalling.
This sourceStandard pharmacology text distinguishing receptor recognition (binding/affinity) from activation (agonist efficacy, the conformational change), the recognition-versus-activation separation at the core of receptor antagonism.
- The recognition interface is the site's shape complementarity; the activation function is the conformational change that, in the native agonist, opens downstream signalling.
- Therapeutic Window
- Therapeutic-window reasoning, as Rang, Dale, Ritter, Flower, and Henderson (2018) systematize in their textbook treatment of pharmacology, proceeds by a sequence of steps: (1) specifying the efficacy criterion and measuring or modeling the dose-response curve for the intended effect; (2) identifying and measuring all relevant toxicity or adverse-effect dose-response curves (toxicity endpoints often outnumber efficacy endpoints); (3) estimating MED and MTD from clinical data, preclinical studies, or dose-escalation trials; (4) computing the window width and therapeutic index as a quantitative measure of the separation; (5) characterizing the variability in MED and MTD across the target population (inter-individual variability, age, organ function, genetics); (6) translating the quantitative window into a dosing regimen or operating policy (target dose, dose range, monitoring frequency); (7) identifying context-specific factors (drug interactions, organ dysfunction, comedications) that shift the window; (8) designing or selecting widening techniques (formulation optimization, dosing schedule modification, combination therapy, sequencing) if the baseline window is unacceptably narrow.
This sourceStandard pharmacology textbook: systematizes the reasoning sequence from dose-response characterization through MED/MTD estimation, therapeutic-index calculation, and population-variability adjustment to dosing-regimen design.
- Therapeutic-window reasoning, as Rang, Dale, Ritter, Flower, and Henderson (2018) systematize in their textbook treatment of pharmacology, proceeds by a sequence of steps: (1) specifying the efficacy criterion and measuring or modeling the dose-response curve for the intended effect; (2) identifying and measuring all relevant toxicity or adverse-effect dose-response curves (toxicity endpoints often outnumber efficacy endpoints); (3) estimating MED and MTD from clinical data, preclinical studies, or dose-escalation trials; (4) computing the window width and therapeutic index as a quantitative measure of the separation; (5) characterizing the variability in MED and MTD across the target population (inter-individual variability, age, organ function, genetics); (6) translating the quantitative window into a dosing regimen or operating policy (target dose, dose range, monitoring frequency); (7) identifying context-specific factors (drug interactions, organ dysfunction, comedications) that shift the window; (8) designing or selecting widening techniques (formulation optimization, dosing schedule modification, combination therapy, sequencing) if the baseline window is unacceptably narrow.
Verification¶
This reference passed the adversarial substantiation pipeline: it was checked to exist and to support the claim it is attached to. See how references were verified.
Links previously used in the corpus¶
Before the registry existed this work was also linked 1 other way.
Registry ID ref:d8e20f321fd0 · see in the full table